A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity
2024
Nature Neuroscience
Benjamin L. L. Clayton, James D. Kristell, Kevin C. Allan, Erin F. Cohn, Molly Karl, Andrew D. Jerome, Eric Garrison, Yuka Maeno-Hikichi, Annalise M. Sturno, Alexis Kerr, H. Elizabeth Shick, Jesse A. Sepeda, Eric C. Freundt, Andrew R. Sas, Benjamin M. Segal, Robert H. Miller & Paul J. Tesar
2023
bioRxiv (pre-print)
Clayton BLL, Barbar L, Sapar M, Rusielewicz T, Kalpana K, Migliori B; NYSCF Global Stem Cell Array® Team; Paull D, Brenner K, Moroziewicz D, Sand IK, Casaccia P, Tesar PJ, Fossati V.
2023
bioRxiv (pre-print)
Scavuzzo MA, Letai KC, Maeno-Hikichi Y, Wulftange WJ, Shah IK, Rameshbabu JS, Tomar A, Shick HE, Shah AK, Xiong Y, Cohn EF, Allan KC, Tesar PJ.
2023
bioRxiv (pre-print)
Cohn EF, Clayton BLL, Madhavan M, Yacoub S, Federov Y, Paul-Friedman K, Shafer TJ, Tesar PJ.
2022
bioRxiv (pre-print)
Allan KC, Miller TE, Morton AR, Scavuzzo MA, Elitt ME, Clayton BLL, Hu LR, Vrabic JK, Olsen HE, Factor DC, Henninger JE, Young RA, Lin CY, Scacheri PC, Tesar PJ.
2022
Nature Communications
Martin S, Allan KC, Pinkard O, Sweet T, Tesar PJ, Coller J.
2022
bioRxiv (pre-print)
Clayton BLL, Kristell JD, Allan KC, Karl M, Garrison E, Maeno-Hikichi Y, Sturno AM, Shick HE, Miller RH, Tesar PJ.
2021
Current Opinion in Cell Biology
Clayton BLL, Tesar PJ.
2021
Cell Stem Cell
Allan KC, Hu LR, Scavuzzo MA, Morton AR, Gevorgyan AS, Cohn, E., Clayton BLL, Bederman I, Hung S, Bartels CF, Madhavan M, Tesar PJ.
2020
bioRxiv (pre-print)
Allan KC, Hu LR, Morton AR, Scavuzzo MA, Gevorgyan AS, Clayton BLL, Bederman I, Hung S, Bartels CF, Madhavan M, Tesar PJ.
2020
Nature
Elitt MS, Barbar L, Shick E, Powers BE, Maeno-Hikitchi Y, Madhavan M, Allan KC, Nawash BS, Gevorgyan AS, Hung S, Nevin ZS, Olsen HE, Hitomi M, Schlatzer DM, Zhao HT, Swayze A, LePage DF, Jiang W, Conlon RA, Rigo F, Tesar PJ.
2020
Cell
Factor DC, Barbeau AM, Allan KC, Hu LR, Madhavan M, Hoang AT, Hazel KEA, Hall PA, Nisraiyya S, Najm FJ, Miller TE, Nevin ZS, Karl RT, Lima BR, Song Y, Sibert AG, Dhillon GK, Volsko C, Bartels CF, Adams DJ, Dutta R, Gallagher MD, Phu W, Kozlenkov A, Dracheva S, Scacheri PC, Tesar PJ, Corradin O.
2020
Pathogens
Foliaki ST, Groveman BR, Yuan J, Walters R, Zhang S, Tesar P, Zou W, Haigh CL.
2020
Neurodevelopmental Disorders (Book)
Editors: Rubenstein J, Rakic P, Chen B, Kwan KY,
Clayton BL, Allan KC, Nevin ZS, Elitt MS, Tesar PJ.
2019
Cell Reports
Tripathi A, Volsko C, Garcia JP, Agirre E, Allan KC, Tesar PJ, Trapp BD, Castelo-Branco G, Sim FJ, Dutta R.
2019
Frontiers in Neuroscience
Boshans LL, Factor DC, Singh V, Liu J, Zhao C, Mandoiu I, Lu QR, Casaccia P, Tesar PJ, Nishiyama A.
2019
Cell Reports
Liu Z, Osipovitch M, Benraiss A, Huynh NPT, Foti R, Bates J, Chandler-Militello D, Findling RL, Tesar PJ, Nedergaard M, Windrem MS, Goldman SA.
2019
Cell Chemical Biology
Allimuthu D, Hubler Z, Najm FJ, Tang H, Bederman I, Seibel W, Tesar PJ, Adams DJ.
2019
Expert Review of Neurotherapeutics
Baldassari LE, Feng J, Clayton BLL, Oh SH, Sakaie K, Tesar PJ, Wang Y, Cohen JA.
2018
bioRxiv (pre-print)
Elitt MS, Barbar L, Shick E, Powers BE, Maeno-Hikitchi Y, Madhavan M, Allan KC, Nawash BS, Nevin ZS, Olsen HE, Hitomi M, LePage DF, Jiang W, Conlon RA, Rigo F, Tesar PJ.
2018
Glia
Gotoh H, Wood WM, Patel KD, Factor DC, Boshans LL, Nomura T, Tesar PJ, Ono K, Nishiyama A.
2018
Nature Communications
Lager AM, Corradin OG, Cregg JM, Elitt MS, Shick HE, Clayton BLL, Allan KC, Olsen HE, Madhavan M, Tesar PJ.
2018
Stem Cell Reports
Elitt MS, Shick HE, Madhavan M, Allan KC, Clayton BLL, Weng C, Miller TE, Factor DC, Barbar L, Nawash BS, Nevin ZS, Lager AM, Li Y, Jin F, Adams DJ, Tesar PJ.
2018
Nature Methods
Madhavan M, Nevin ZS, Shick HE, Garrison E, Clarkson-Paredes C, Karl M, Clayton BLL, Factor DC, Allan KC, Barbar L, Jain T, Douvaras P, Fossati V, Miller RH, Tesar PJ.
2018
Journal of Clinical Investigation
Chai S, Wan X, Ramirez-Navarro A, Tesar PJ, Kaufman ES, Ficker E, George AL Jr, Deschênes I.
2018
Nature
Hubler Z, Allimuthu D, Bederman I, Elitt MS, Madhavan M, Allan KC, Shick HE, Garrison E, T Karl M, Factor DC, Nevin ZS, Sax JL, Thompson MA, Fedorov Y, Jin J, Wilson WK, Giera M, Bracher F, Miller RH, Tesar PJ, Adams DJ.
2018
Human Molecular Genetics
Elitt MS, Barbar L, Tesar PJ.
2017
Cell Stem Cell
Windrem MS, Osipovitch M, Liu Z, Bates J, Chandler-Militello D, Zou L, Munir J, Schanz S, McCoy K, Miller RH, Wang S, Nedergaard M, Findling RL, Tesar PJ, Goldman SA.
2017
Nature
Miller TE, Liau BB, Wallace LC, Morton AR, Xie Q, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q, Mack SC, Hubert CG, Gillespie SM, Flavahan WA, Hoffmann T, Thummalapalli R, Hemann MT, Paddison PJ, Horbinski CM, Zuber J, Scacheri PC, Bernstein BE, Tesar PJ, Rich JN.
2017
American Journal of Human Genetics
Nevin ZS, Factor DC, Karl RT, Douvaras P, Laukka J, Windrem MS, Goldman SA, Fossati V, Hobson GM, Tesar PJ.
2017
Tissue Engineering Part A
Somoza RA, Correa D, Labat I, Sternberg H, Forrest ME, Khalil AM, West MD, Tesar P, Caplan AI.
2017
Cell Stem Cell
Tesar PJ, Scacheri PC.
2017
Lancet
Cohen JA, Tesar PJ.
2017
Brain
Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis.
2017
Stem Cell Technologies in Neuroscience
Neuromethods, Springer
Karl R, Lager A, Najm F, Tesar PJ.
2017
Stem Cells
Osorio MJ, Rowitch DH, Tesar PJ, Wernig M, Windrem MS, Goldman SA.
2016
Journal of NeuroVirology
Benner B, Martorell AJ, Mahadevan P, Najm FJ, Tesar PJ, Freundt EC.
2016
Brain and Behavior
Sheng Y, Filichia E, Shick E, Preston KL, Phillips KA, Cooperman L, Lin Z, Tesar PJ, Hoffer B, Luo Y.
2016
The American Journal of Psychiatry
Sheng Y, Filichia E, Shick E, Preston KL, Phillips KA, Cooperman L, Lin Z, Tesar PJ, Hoffer BJ, Luo Y.
2016
Stem Cell Reports
Tesar PJ.
2015
Cancer Cell
Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS, Hubert CG, Mack SC, Jarrar AM, Karl RT, Rosager AM, Nixon AM, Tesar PJ, Hamerlik P, Kristensen BW, Horbinski C, Connor JR, Fox PL, Lathia JD, Rich JN.
2015
Nature
Najm FJ, Madhavan M, Zaremba A, Shick E, Karl RT, Factor DC, Miller TE, Nevin ZS, Kantor C, Sargent A, Quick KL, Schlatzer DM, Tang H, Papoian R, Brimacombe KR, Shen M, Boxer MB, Jadhav A, Robinson AP, Podojil JR, Miller SD, Miller RH, Tesar PJ.
2015
Science Translational Medicine
Tesar PJ.
2015
Science Translational Medicine
Tesar PJ.
2014
Cell Stem Cell
Factor DC, Corradin O, Zentner GE, Saiakhova A, Song L, Chenoweth JG, McKay RD, Crawford GE, Scacheri PC, Tesar
2014
Proceedings of the National Academy of Sciences
Ware CB, Nelson AM, Mecham B, Hesson J, Zhou W, Jonlin EC, Jimenez-Caliani AJ, Deng X, Cavanaugh C, Cook S, Tesar PJ, Okada J, Margaretha L, Sperber H, Choi M, Blau CA, Treuting PM, Hawkins RD, Cirulli V, Ruohola-Baker H.
2014
Cell Reports
Boles NC, Hirsch SE, Le S, Corneo B, Najm F, Minotti AP, Wang Q, Lotz S, Tesar PJ, Fasano CA.
2014
Science Translational Medicine
Tesar PJ.
2014
Science Translational Medicine
Tesar PJ.
2014
Science Translational Medicine
Tesar PJ.
2014
Science Translational Medicine
Tesar PJ.
2014
Science Translational Medicine
Tesar PJ.
2014
Science Translational Medicine
Tesar PJ.
2014
Science Translational Medicine
Tesar PJ.
2013
Journal of Biological Chemistry
Maeda T, Lee MJ, Palczewska G, Marsili S, Tesar PJ, Palczewski K, Takahashi M, Maeda A.
2013
BMC Genetics
Zechel JL, Doerner SK, Lager A, Tesar PJ, Heaney JD, Nadeau JH.
2013
Nature Biotechnology
Najm FJ, Lager AM, Zaremba A, Wyatt K, Caprariello AV, Factor DC, Karl RT, Maeda T, Miller RH, Tesar PJ.
2013
Stem Cells
Park KS, Cha Y, Kim CH, Ahn HJ, Kim D, Ko S, Kim KH, Chang MY, Ko JH, Noh YS, Han YM, Kim J, Song J, Kim JY, Tesar PJ, Lanza R, Lee KA, Kim KS
2013
Methods in Molecular Biology
Factor DC, Najm FJ, Tesar PJ.
2013
Stem Cell Research
Mallon BS, Chenoweth JG, Johnson KR, Hamilton RS, Tesar PJ, Yavatkar AS, Tyson LJ, Park K, Chen KG, Fann YC, McKay RD.
2013
Cell Stem Cell
Tesar PJ.
2013
Molecular Biology of Long Non-coding RNAs, Springer
Factor D, Tesar PJ, Khalil A.
Tesar Lab
We firmly believe that the internet should be available and accessible to anyone, and are committed to providing a website that is accessible to the widest possible audience, regardless of circumstance and ability.
To fulfill this, we aim to adhere as strictly as possible to the World Wide Web Consortium’s (W3C) Web Content Accessibility Guidelines 2.1 (WCAG 2.1) at the AA level. These guidelines explain how to make web content accessible to people with a wide array of disabilities. Complying with those guidelines helps us ensure that the website is accessible to all people: blind people, people with motor impairments, visual impairment, cognitive disabilities, and more.
This website utilizes various technologies that are meant to make it as accessible as possible at all times. We utilize an accessibility interface that allows persons with specific disabilities to adjust the website’s UI (user interface) and design it to their personal needs.
Additionally, the website utilizes an AI-based application that runs in the background and optimizes its accessibility level constantly. This application remediates the website’s HTML, adapts Its functionality and behavior for screen-readers used by the blind users, and for keyboard functions used by individuals with motor impairments.
If you’ve found a malfunction or have ideas for improvement, we’ll be happy to hear from you. You can reach out to the website’s operators by using the following email
Our website implements the ARIA attributes (Accessible Rich Internet Applications) technique, alongside various different behavioral changes, to ensure blind users visiting with screen-readers are able to read, comprehend, and enjoy the website’s functions. As soon as a user with a screen-reader enters your site, they immediately receive a prompt to enter the Screen-Reader Profile so they can browse and operate your site effectively. Here’s how our website covers some of the most important screen-reader requirements, alongside console screenshots of code examples:
Screen-reader optimization: we run a background process that learns the website’s components from top to bottom, to ensure ongoing compliance even when updating the website. In this process, we provide screen-readers with meaningful data using the ARIA set of attributes. For example, we provide accurate form labels; descriptions for actionable icons (social media icons, search icons, cart icons, etc.); validation guidance for form inputs; element roles such as buttons, menus, modal dialogues (popups), and others. Additionally, the background process scans all the website’s images and provides an accurate and meaningful image-object-recognition-based description as an ALT (alternate text) tag for images that are not described. It will also extract texts that are embedded within the image, using an OCR (optical character recognition) technology. To turn on screen-reader adjustments at any time, users need only to press the Alt+1 keyboard combination. Screen-reader users also get automatic announcements to turn the Screen-reader mode on as soon as they enter the website.
These adjustments are compatible with all popular screen readers, including JAWS and NVDA.
Keyboard navigation optimization: The background process also adjusts the website’s HTML, and adds various behaviors using JavaScript code to make the website operable by the keyboard. This includes the ability to navigate the website using the Tab and Shift+Tab keys, operate dropdowns with the arrow keys, close them with Esc, trigger buttons and links using the Enter key, navigate between radio and checkbox elements using the arrow keys, and fill them in with the Spacebar or Enter key.Additionally, keyboard users will find quick-navigation and content-skip menus, available at any time by clicking Alt+1, or as the first elements of the site while navigating with the keyboard. The background process also handles triggered popups by moving the keyboard focus towards them as soon as they appear, and not allow the focus drift outside it.
Users can also use shortcuts such as “M” (menus), “H” (headings), “F” (forms), “B” (buttons), and “G” (graphics) to jump to specific elements.
We aim to support the widest array of browsers and assistive technologies as possible, so our users can choose the best fitting tools for them, with as few limitations as possible. Therefore, we have worked very hard to be able to support all major systems that comprise over 95% of the user market share including Google Chrome, Mozilla Firefox, Apple Safari, Opera and Microsoft Edge, JAWS and NVDA (screen readers).
Despite our very best efforts to allow anybody to adjust the website to their needs. There may still be pages or sections that are not fully accessible, are in the process of becoming accessible, or are lacking an adequate technological solution to make them accessible. Still, we are continually improving our accessibility, adding, updating and improving its options and features, and developing and adopting new technologies. All this is meant to reach the optimal level of accessibility, following technological advancements. For any assistance, please reach out to